Page last updated: 2024-12-05

metolazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metolazone is a thiazide-like diuretic used to treat high blood pressure and fluid retention. It is a potent diuretic that works by blocking the reabsorption of sodium and chloride in the kidneys, leading to increased urine output. Metolazone is often used in combination with other diuretics, such as furosemide, to achieve greater diuresis. The synthesis of metolazone involves a multi-step process starting with the reaction of 2-chloro-4-nitroaniline with chloroacetyl chloride, followed by a series of reactions to introduce the thiazide ring and the sulfonamide group. Metolazone is studied for its potential use in treating various conditions, including hypertension, congestive heart failure, and nephrotic syndrome. The drug is often studied in combination with other medications, particularly in the treatment of edema associated with heart failure. Research is ongoing to investigate the efficacy and safety of metolazone in various patient populations and to understand its mechanisms of action in greater detail.'

Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4170
CHEMBL ID878
CHEBI ID64354
SCHEMBL ID40558
MeSH IDM0013684

Synonyms (176)

Synonym
6-quinazolinesulfonamide, 1,2,3,4-tetrahydro-7-chloro-2-methyl-4-oxo-3-o-tolyl-
metenix
einecs 241-539-3
zaroxolyn
hsdb 3367
diulo
mykrox
oldren
metolazona [inn-spanish]
metolazonum [inn-latin]
6-quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-
microx
sr 720-22
metalozone
sr-720-22
6-quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-
brn 0965506
MLS002153316
smr001230730
MLS002154200
AB00052055-08
BRD-A61793559-001-05-7
KBIO1_000275
DIVK1C_000275
metolazone, >=98% (hplc), solid
SPECTRUM_000456
17560-51-9
metolazone
PRESTWICK_333
cas-17560-51-9
IDI1_000275
SPECTRUM5_001237
BSPBIO_002422
PRESTWICK3_000112
bdbm25899
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
AB00052055
2-methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
DB00524
7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide
zaroxolyn (tn)
D00431
metolazone (jan/usp/inn)
PRESTWICK2_000112
BSPBIO_000124
NCGC00093985-03
NCGC00093985-02
NCGC00093985-01
NCGC00093985-04
KBIOGR_000897
KBIO2_000936
KBIOSS_000936
KBIO2_006072
KBIO2_003504
PRESTWICK1_000112
SPBIO_001842
NINDS_000275
PRESTWICK0_000112
SPECTRUM2_001741
SPECTRUM4_000229
SPBIO_002063
SPECTRUM2300325
BPBIO1_000138
NCGC00093985-05
NCGC00093985-06
HMS2093P14
NCGC00093985-08
chebi:64354 ,
metozalone
nsc-759581
normelan
CHEMBL878
metazoline
HMS500N17
HMS1568G06
HMS1922L16
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
NCGC00093985-07
HMS3261J22
HMS2095G06
metolazone [usan:usp:inn:ban:jan]
5-25-09-00212 (beilstein handbook reference)
nsc 759581
metolazonum
unii-tz7v40x7vx
tz7v40x7vx ,
metolazona
tox21_113526
nsc759581
pharmakon1600-02300325
tox21_110186
dtxsid6045167 ,
dtxcid4025167
7-chloro-2-methyl-4-oxo-3-(o-tolyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
xuret
metalazone
HMS2230J15
CCG-39450
BCP9000920
BCPP000166
NCGC00093985-10
LP00610
S1610
AKOS015897109
HMS3373C11
gtpl4838
metolazone [ep impurity]
metolazone [mi]
metolazone [hsdb]
metolazone [inn]
metolazone [jan]
metolazone [vandf]
metolazone [usan]
metolazone [usp-rs]
metolazone [orange book]
metolazone [usp monograph]
metolazone [mart.]
metolazone [who-dd]
metolazone [ep monograph]
HY-B0209
SCHEMBL40558
NCGC00093985-11
tox21_110186_1
KS-5139
NCGC00261295-01
tox21_500610
Q-201399
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydro-6-quinazolinesulfonamide #
AB00052055_09
AB00052055_10
mfcd00069304
metolazone, (-)-
metolazone, (+)-
NN9U607695 ,
6-quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (-)-
NM7V2Y3G0U ,
6-quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (+)-
56436-31-8
unii-nm7v2y3g0u
56436-32-9
unii-nn9u607695
sr-05000001765
SR-05000001765-7
metolazone, united states pharmacopeia (usp) reference standard
HMS3655M09
SR-05000001765-4
SR-05000001765-1
metolazone, european pharmacopoeia (ep) reference standard
metolazone for system suitability, european pharmacopoeia (ep) reference standard
metolazone; (2rs)-7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SBI-0051460.P002
HMS3712G06
SW196612-3
-tetrahydroquinazoline-6-sulfonamide
7-chloro-2-methyl-4-oxo-3-o-tolyl-1,2,3,4
BCP21574
metolazone (zaroxolyn)
AS-13016
Q1169561
BRD-A61793559-001-08-1
SDCCGSBI-0051460.P003
NCGC00093985-20
HMS3744I19
EN300-23818025
metolazon
metolazone (usan:usp:inn:ban:jan)
metolazone (ep monograph)
metolazone (usp-rs)
metolazonum (inn-latin)
c03ba08
metolazone (ep impurity)
metolazona (inn-spanish)
7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-tolyl-6-quinazolinesulfonamide
metolazone (usp monograph)
metolazone (mart.)

Research Excerpts

Overview

Metolazone is a thiazide-type diuretic that is characterized by slow and sometimes erratic absorption. It has a therapeutic effect on blood pressure (BP) in human essential hypertension without causing a natriuresis.

ExcerptReferenceRelevance
"Metolazone is a diuretic, saluretic and antihypertensive chemical compound from the quinazoline category that possesses medicinal features similar to those of other thiazide diuretic drugs. "( Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population.
Feng, Y; Geng, H; Li, X; Liu, Y; Wang, R; Wen, A; Zhang, W; Zhao, N; Zheng, H, 2017
)
2.14
"Metolazone is a thiazide-type diuretic that is characterized by slow and sometimes erratic absorption when administered as the Zaroxylyn product."( Metolazone and its role in edema management.
Sica, DA,
)
2.3
"Metolazone is a potent thiazide-like diuretic. "( Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.
Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005
)
2.07
"Metolazone is a diuretic/antihypertensive agent, which has a therapeutic effect on blood pressure (BP) in human essential hypertension without causing a natriuresis."( Beneficial effects of metolazone in a rat model of preeclampsia.
Danchuk, S; Ianosi-Irimie, M; Pridjian, C; Pridjian, G; Puschett, JB; Vu, HV, 2006
)
1.37
"Metolazone is an anthracrene acid derivate and manifests a dual diuretic effect on the proximal and distal tubule with a minimal kaluretic effect."( The evaluation of the diuretic action of parenteral formulations of metolazone.
Cvetanovic, I; Molnar, J; Ranade, V; Somberg, J; Whelton, A,
)
1.09

Toxicity

ExcerptReferenceRelevance
" The side-effect score for edema was lower with ISR plus diuretics than with other combinations, whereas the ACE inhibitor was associated with a higher score for cough."( Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
Lüscher, TF; Waeber, B, 1993
)
0.29
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Oral metolazone was noninferior to IV chlorothiazide for enhancing net UOP in patients with ADHF and loop diuretic resistance and was similarly safe with regard to renal function and electrolyte abnormalities."( Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.
Devabhakthuni, S; Ivaturi, V; Jiang, A; Liu, T; Reed, BN; Shulenberger, CE, 2016
)
1.19

Pharmacokinetics

Study aimed to examine pharmacokinetic characteristics, safety characteristic, and tolerability of metolazone in healthy Chinese subjects after single and multiple doses taken orally.

ExcerptReferenceRelevance
" The administration of I or S with M significantly blunted sodium excretion on a purely pharmacodynamic basis while the decline in urinary potassium excretion upon addition of I to M related probably to an attenuation of braking phenomenon induced kaliuresis."( The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.
Gehr, TW; Kish, C; Ripley, EB; Sica, DA; Wade, J; Wallace, H, 1994
)
0.51
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The described method was successfully applied to preclinical pharmacokinetic studies of analytes after an oral administration of mixture of MET (1 mg/kg) and LOS (10 mg/kg) in rats."( Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS.
Dubey, R; Ghosh, M; Muthukrishnan, V; Sinha, BN, 2015
)
0.67
" This study aimed to examine the pharmacokinetic characteristics, safety characteristic, and tolerability of metolazone in healthy Chinese subjects after single and multiple doses taken orally as well as the effects that food and gender have on oral metolazone pharmacokinetic parameters."( Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population.
Feng, Y; Geng, H; Li, X; Liu, Y; Wang, R; Wen, A; Zhang, W; Zhao, N; Zheng, H, 2017
)
0.91
"5 mg, 1 mg, or 2 mg metolazone yielded linear plasma pharmacokinetic properties in healthy Chinese subjects."( Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population.
Feng, Y; Geng, H; Li, X; Liu, Y; Wang, R; Wen, A; Zhang, W; Zhao, N; Zheng, H, 2017
)
1.02

Bioavailability

ExcerptReferenceRelevance
" Diminished bioavailability of metolazone or tubular secretion likely accounted for this disparity in metolazone excretion."( Metolazone pharmacokinetics and pharmacodynamics in renal transplantation.
Brater, DC; Davis, J; Fakhry, I; Gehr, TW; Sica, DA; Wallace, HJ, 1991
)
2.01
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Treatment was associated with mild transient hypokalaemia in 7 patients, and hyponatraemia and renal impairment in 1, for whom metolazone dosage had to be reduced. Blood pressure lowering may be inconsistent at these dosage levels.

ExcerptRelevanceReference
" The natriuretic action of MET was not enhanced by administration of an increased dosage (1 approximately 5 mg/kg)."( [Pharmacological study on diuretic action of 2-methyl-3-(o-tolyl)-6-sulfamyl-7-chloro-1, 2, 3, 4-tetrahydro-4-quinazolinone (metolazone) (author's transl)].
Fukuhara, A; Matsumura, Y; Morimoto, S, 1978
)
0.46
" Treatment was associated with mild transient hypokalaemia in 7 patients, and hyponatraemia and renal impairment in 1, for whom metolazone dosage had to be reduced."( Metolazone in treatment of severe refractory congestive cardiac failure.
Arter, WJ; Field, MJ; Kiyingi, A; Lawrence, JR; Pawsey, CC; Yiannikas, J, 1990
)
1.93
"5 mg/day of metolazone or 25 mg/day of chlorthalidone are effective antihypertensive agents but that blood pressure lowering may be inconsistent at these dosage levels."( Low-dose diuretic therapy for hypertension.
Moser, M, 1986
)
0.65
" Urine samples were obtained over 36 hours post-metolazone dosing for the determination of sodium, potassium and metolazone concentration."( The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.
Gehr, TW; Kish, C; Ripley, EB; Sica, DA; Wade, J; Wallace, H, 1994
)
0.76
"The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1996
)
0.59
"5 to 200 mg), leaving no clear dosing recommendation."( Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.
Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005
)
0.63
"Two robust and selective stability-indicating chromatographic methods were developed and validated for the determination of metolazone in drug substance and pharmaceutical dosage form in the presence of its degradation products."( Development and Validation of Two Robust Stability-Indicating Chromatographic Methods for Determination of Metolazone in Drug Substance and Pharmaceutical Dosage Form in the Presence of Its Degradation Products and Characterization of Main Degradation Pro
Abdel-Ghany, R; Abdelkawy, M; Sayed, M; Zaazaa, HE, 2020
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
ion transport inhibitorA compound which inhibits the movement of an ion across an energy-transducing cell membrane.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Metolazone Action Pathway319

Protein Targets (49)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency29.45480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency29.45480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
endonuclease IVEscherichia coliPotency177.82800.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency39.48240.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID493106
NFKB1 protein, partialHomo sapiens (human)Potency14.12540.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
AR proteinHomo sapiens (human)Potency10.68220.000221.22318,912.5098AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency29.90330.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency37.64990.531815.435837.6858AID504845
pregnane X nuclear receptorHomo sapiens (human)Potency5.30800.005428.02631,258.9301AID1346982
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00060.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency42.561523.934123.934123.9341AID1967
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency20.26770.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.11220.01789.637444.6684AID588834
flap endonuclease 1Homo sapiens (human)Potency29.93490.133725.412989.1251AID588795
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency26.20000.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency26.20001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki22.06390.00021.10439.9000AID1798598
Carbonic anhydrase 1Homo sapiens (human)Ki22.06390.00001.372610.0000AID1798598
Carbonic anhydrase 2Homo sapiens (human)Ki22.06390.00000.72369.9200AID1798598
Carbonic anhydrase 3Homo sapiens (human)Ki22.06390.00022.010210.0000AID1798598
Carbonic anhydrase 4Homo sapiens (human)Ki22.06390.00021.97209.9200AID1798598
Carbonic anhydrase 6Homo sapiens (human)Ki22.06390.00011.47109.9200AID1798598
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki22.06390.00001.27259.9000AID1798598
Carbonic anhydrase 7Homo sapiens (human)Ki20.36680.00021.37379.9000AID1060765; AID1798598
Carbonic anhydrase 9Homo sapiens (human)Ki22.06390.00010.78749.9000AID1798598
Carbonic anhydrase 13Mus musculus (house mouse)Ki22.06390.00021.39749.9000AID1798598
Carbonic anhydrase 14Homo sapiens (human)Ki22.06390.00021.50999.9000AID1798598
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki22.06390.00001.34129.9700AID1798598
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Kinact0.00540.00300.66749.6000AID328983
Carbonic anhydrase 1Homo sapiens (human)Kinact54.00000.01000.93878.6000AID328974
Carbonic anhydrase 2Homo sapiens (human)Kinact2.00000.00300.794610.0000AID328975
Carbonic anhydrase 4Homo sapiens (human)Kinact0.21600.07402.39348.5900AID328977
Carbonic anhydrase 6Homo sapiens (human)Kinact1.71400.00090.72615.3000AID328980
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kinact0.75000.02000.85809.4000AID328978
Carbonic anhydrase 7Homo sapiens (human)Kinact0.00210.00020.28525.7300AID328981
Carbonic anhydrase 9Homo sapiens (human)Kinact0.32000.00500.31976.6700AID328982
Carbonic anhydrase 13Mus musculus (house mouse)Kinact0.01500.01300.56698.2300AID328984
Carbonic anhydrase 14Homo sapiens (human)Kinact5.43200.00021.44958.5900AID328985
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kinact0.31200.00900.92319.0400AID328979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (181)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221981Efflux ratio of permeability from apical to basolateral over basolateral to apical side of MDCK cells expressing BCRP2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID328983Inhibition of human catalytic domain carbonic anhydrase 122008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID328982Inhibition of human catalytic domain carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328975Inhibition of human full length carbonic anhydrase 22008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID1060765Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1221976Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221971Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221975Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221968Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328979Inhibition of human full length carbonic anhydrase 5B2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1221972Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID328976Inhibition of human full length carbonic anhydrase 32008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221980Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID328978Inhibition of human full length carbonic anhydrase 5A2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID328985Inhibition of human full length carbonic anhydrase 142008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1221973Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221978Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221970Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID328977Inhibition of human full length carbonic anhydrase 42008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID328981Inhibition of human full length carbonic anhydrase 72008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1221969Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID328980Inhibition of human full length carbonic anhydrase 62008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1221979Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221977Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID328974Inhibition of human full length carbonic anhydrase 12008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328984Inhibition of mouse full length carbonic anhydrase 132008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1798598CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (229)

TimeframeStudies, This Drug (%)All Drugs %
pre-199098 (42.79)18.7374
1990's36 (15.72)18.2507
2000's27 (11.79)29.6817
2010's49 (21.40)24.3611
2020's19 (8.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.04 (24.57)
Research Supply Index5.60 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index171.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (13.50%)5.53%
Reviews7 (2.95%)6.00%
Case Studies32 (13.50%)4.05%
Observational1 (0.42%)0.25%
Other165 (69.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. [NCT02620384]Phase 3147 participants (Actual)Interventional2015-10-01Terminated(stopped due to Limited resources available to met accrual goal.)
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance (P-Value-AHF): A Multicentre, Randomized, Parallel-group, Open-label Trial [NCT05986773]Phase 475 participants (Anticipated)Interventional2023-10-10Recruiting
[NCT02047422]0 participants (Actual)Interventional2014-01-31Withdrawn(stopped due to One of the diuretic which is planned to be used in the study is no longer available.)
Efficacy of Diuretics in Kidney Disease [NCT04542304]Phase 250 participants (Anticipated)Interventional2021-03-01Recruiting
Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance [NCT03574857]Phase 45 participants (Actual)Interventional2018-06-01Terminated(stopped due to Low enrollment)
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
AiDing Diuresis wIth Tolvaptan (ADD-IT) [NCT02646540]Phase 114 participants (Actual)Interventional2016-01-31Completed
Ertugliflozin in Chronic Heart Failure: Cardio-renal and Diuretic Effects [NCT04438213]Phase 260 participants (Anticipated)Interventional2021-03-10Recruiting
Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (5 mg; Mylan) and Zaroloxyn® Tablets (5 mg; Celltech) in Healthy Volunteers [NCT00649181]Phase 152 participants (Actual)Interventional2003-10-31Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (10 mg; Mylan) and Zaroloxyn® Tablets (10 mg; Celltech) in Healthy Volunteers [NCT00650195]Phase 156 participants (Actual)Interventional2004-02-29Completed
A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients [NCT00690521]Phase 413 participants (Anticipated)Interventional2003-01-31Recruiting
Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (2.5 mg; Mylan) and Zaroloxyn® Tablets (2.5 mg; Celltech) in Healthy Volunteers [NCT00649051]Phase 152 participants (Actual)Interventional2002-12-31Completed
Diuresis Efficacy in Ambulatory Chronic Heart Failure Patients With Volume Overload- Intra -Patient Comparison of Three Diuretics Regimens [NCT05904808]Phase 442 participants (Actual)Interventional2023-04-19Active, not recruiting
Early Sequential Nephron Blockade Versus Standard Diuretic Treatment in Acute Heart Failure [NCT04163588]Phase 3310 participants (Anticipated)Interventional2019-10-01Recruiting
Addition of Oral Metolazone to Intermittent Intravenous Furosemide Versus Transition to Continuous Infusion Furosemide in Acute Decompensated Heart Failure Patients Experiencing an Inadequate Response to Therapy [NCT00904488]Phase 411 participants (Actual)Interventional2008-10-31Terminated(stopped due to Difficult recruitment)
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload - A Randomized Clinical Trial [NCT06166654]Phase 4939 participants (Anticipated)Interventional2024-04-01Not yet recruiting
[NCT01817803]0 participants (Actual)Interventional2013-03-31Withdrawn
Sodium Glucose Cotransporter-2 Inhibitor DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance: a Multi-centre, Open-label, Randomised Controlled Clinical Trial [NCT04860011]Phase 361 participants (Actual)Interventional2021-04-27Active, not recruiting
Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing With Furosemide: a Pilot Study [NCT03746002]Phase 43 participants (Actual)Interventional2019-01-01Terminated(stopped due to Insufficient rate of patient enrollment/accrual.)
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Stop Hypernatremia, Use Metolazone for Aggressive, Controlled, Effective Diuresis [NCT01617798]0 participants (Actual)Interventional2012-06-30Withdrawn(stopped due to Investigator departed organization)
Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure [NCT02606253]Phase 460 participants (Actual)Interventional2016-02-29Completed
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF): A Multicenter, Randomized Controlled Trial. [NCT05633758]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn(stopped due to no participants enrolled)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00904488 (14) [back to overview]30-day All-cause Mortality
NCT00904488 (14) [back to overview]Length of Hospitalization
NCT00904488 (14) [back to overview]Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)
NCT00904488 (14) [back to overview]Rehospitalization at 30 Days
NCT00904488 (14) [back to overview]Time to Return to Baseline Weight
NCT00904488 (14) [back to overview]Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic
NCT00904488 (14) [back to overview]Physician Global Assessment Scale
NCT00904488 (14) [back to overview]Blood Urea Nitrogen (BUN)
NCT00904488 (14) [back to overview]Daily Net Fluid Output on Days 1, 3, and 4
NCT00904488 (14) [back to overview]Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)
NCT00904488 (14) [back to overview]Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)
NCT00904488 (14) [back to overview]Daily Weight
NCT00904488 (14) [back to overview]Patient Global Assessment Scale
NCT00904488 (14) [back to overview]Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)
NCT02606253 (18) [back to overview]Mean Change in Serum Potassium
NCT02606253 (18) [back to overview]Mean Change in Serum Sodium
NCT02606253 (18) [back to overview]Net Urine Output
NCT02606253 (18) [back to overview]Number of Patients With Cardiac Arrhythmias
NCT02606253 (18) [back to overview]Number of Patients With Escalation of Loop Diuretic Therapy
NCT02606253 (18) [back to overview]Number of Patients With In-hospital Mortality
NCT02606253 (18) [back to overview]Number of Patients With New Inotrope Utilization
NCT02606253 (18) [back to overview]Number of Patients With Renal Replacement Therapy Utilization
NCT02606253 (18) [back to overview]Number of Patients With Symptomatic Hypotension
NCT02606253 (18) [back to overview]Potassium Supplementation
NCT02606253 (18) [back to overview]Weight Change Over 48 Hours
NCT02606253 (18) [back to overview]Number of Patients With Hypokalemia
NCT02606253 (18) [back to overview]Change in eGFR From Baseline to 48 Hours
NCT02606253 (18) [back to overview]Change in Patient Congestion Score
NCT02606253 (18) [back to overview]Change in Serum Chloride From Baseline
NCT02606253 (18) [back to overview]Diuretic Efficiency
NCT02606253 (18) [back to overview]Mean Change in Glomerular Filtration Rate at Discharge
NCT02606253 (18) [back to overview]Mean Change in Serum Creatinine
NCT02620384 (12) [back to overview]All Cause Readmission Within 30 Days
NCT02620384 (12) [back to overview]Change in Weight First 48 Hours
NCT02620384 (12) [back to overview]Fluid Balance at 48 Hours
NCT02620384 (12) [back to overview]Heart Failure Readmission Within 30 Days
NCT02620384 (12) [back to overview]Length of Hospital Stay
NCT02620384 (12) [back to overview]Number of Participants With Magnesium Electrolyte Abnormality Requiring Replacement
NCT02620384 (12) [back to overview]Number of Participants With Potassium Electrolyte Abnormality Requiring Replacement
NCT02620384 (12) [back to overview]Total Dose Diuretics First 48 Hours
NCT02620384 (12) [back to overview]Total Urinary Output at 48 Hours
NCT02620384 (12) [back to overview]Degree of Improvement in Dyspnea at 6, 12, 24, 36 and 48 Hours.
NCT02620384 (12) [back to overview]Number of Participants With Inotrope Administration During First 48 Hours
NCT02620384 (12) [back to overview]All Cause Mortality at 30 Days
NCT03746002 (7) [back to overview]Change in Total Body Weight
NCT03746002 (7) [back to overview]Hypokalemia
NCT03746002 (7) [back to overview]Hypomagnesemia
NCT03746002 (7) [back to overview]Hyponatremia
NCT03746002 (7) [back to overview]24-Hour Urine Output
NCT03746002 (7) [back to overview]Acute Kidney Injury
NCT03746002 (7) [back to overview]Change in Serum Creatinine

30-day All-cause Mortality

(NCT00904488)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Furosemide Dose Escalation0
IVB Loop and PO Thiazide Diuretic0

[back to top]

Length of Hospitalization

(NCT00904488)
Timeframe: Assessed till hospital discharge, an average of 1 week (longest 29 days)

InterventionDays (Mean)
Furosemide Dose Escalation4.75
IVB Loop and PO Thiazide Diuretic11.25

[back to top]

Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)

Patients will be considered a treatment failure if they require additional diuretic (including crossover to the alternative study arm) or require IV vasoactive drug therapy (e.g. vasodilators including nitroglycerin or inotropes) as deemed appropriate/necessary by their medical team. (NCT00904488)
Timeframe: 0-96 hours

InterventionParticipants (Count of Participants)
Furosemide Dose Escalation1
IVB Loop and PO Thiazide Diuretic4

[back to top]

Rehospitalization at 30 Days

(NCT00904488)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Furosemide Dose Escalation1
IVB Loop and PO Thiazide Diuretic1

[back to top]

Time to Return to Baseline Weight

(NCT00904488)
Timeframe: 0-96 hours

InterventionDays (Mean)
Furosemide Dose Escalation1.5
IVB Loop and PO Thiazide Diuretic1.5

[back to top]

Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic

(NCT00904488)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Furosemide Dose Escalation1
IVB Loop and PO Thiazide Diuretic1

[back to top]

Physician Global Assessment Scale

"Scale range: 1-5 Which of the following best describes the patient's overall health state today?~= markedly worse~= worse~= neither better nor worse~= better~= markedly better" (NCT00904488)
Timeframe: Baseline, 24, 48, 72, 96 hours

,
Interventionunits on a scale (Mean)
Baseline24 hr48 hr72 hr96 hr
Furosemide Dose Escalation2.674.2544.54
IVB Loop and PO Thiazide Diuretic2443.753.67

[back to top]

Blood Urea Nitrogen (BUN)

(NCT00904488)
Timeframe: Baseline, 24, 48, 72, 96 hours

,
Interventionmg/dL (Mean)
Baseline24 hr48 hr72 hr96 hr
Furosemide Dose Escalation31.2028.0030.8029.0038.60
IVB Loop and PO Thiazide Diuretic29.8327.6733.1742.0042.67

[back to top]

Daily Net Fluid Output on Days 1, 3, and 4

Daily net fluid output = daily fluid output - daily intake. A negative value means that daily fluid intake was less than the daily fluid output. (NCT00904488)
Timeframe: 0-24, 48-72, 72-96 hrs

,
Interventionml/day (Mean)
0-24 hr48-72 hr72-96 hr
Furosemide Dose Escalation-2226.74-2108.00-2433.33
IVB Loop and PO Thiazide Diuretic-3076.67-409.74-705.33

[back to top]

Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)

(NCT00904488)
Timeframe: 0-24, 24-48, 48-72, 72-96 hrs

Interventionml/mg furosemide received (Mean)
0-24 hr24-48 hr48-72 hr
IVB Loop and PO Thiazide Diuretic17.3521.8825.52

[back to top]

Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)

(NCT00904488)
Timeframe: 0-24, 24-48, 48-72, 72-96 hrs

Interventionml/mg furosemide received (Mean)
0-24 hr24-48 hr48-72 hr72-96 hr
Furosemide Dose Escalation29.358.2825.8443.94

[back to top]

Daily Weight

(NCT00904488)
Timeframe: Baseline (Dry), Baseline, 0-24, 24-48, 48-72, 72-96 hrs

,
InterventionKg (Mean)
Baseline (Dry)Baseline0-24 hr24-48 hr48-72 hr72-96 hr
Furosemide Dose Escalation82.35120.84154.23129.73135.07172.10
IVB Loop and PO Thiazide Diuretic100.82102.57101.0799.08106.7086.87

[back to top]

Patient Global Assessment Scale

"Scale range: 1-5 Which of the following best describes your overall health state today?~= markedly worse~= worse~= neither better nor worse~= better~= markedly better" (NCT00904488)
Timeframe: Baseline, 24, 48, 72, 96 hrs

,
Interventionunits on a scale (Mean)
Baseline24 hr48 hr72 hr96 hr
Furosemide Dose Escalation3.254.23.84.674
IVB Loop and PO Thiazide Diuretic3.674.253.63.754

[back to top]

Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)

Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output. (NCT00904488)
Timeframe: 24-48 hours

InterventionmL/day (Mean)
Furosemide Dose Escalation-1454.60
IVB Loop and PO Thiazide Diuretic-1322.83

[back to top]

Mean Change in Serum Potassium

Mean change in serum potassium (mEq/L) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

InterventionmEq/L (Mean)
Metolazone-0.1
Chlorothiazide-0.2
Tolvaptan0.1

[back to top]

Mean Change in Serum Sodium

Mean change in serum sodium (mEq/L) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

InterventionmEq/L (Mean)
Metolazone-1
Chlorothiazide-1
Tolvaptan4

[back to top]

Net Urine Output

Net urine output from enrollment to the end of study at 48 hours measured in liters (NCT02606253)
Timeframe: 48 hours

Interventionliters (Median)
Metolazone-7.8
Chlorothiazide-8.8
Tolvaptan-9.8

[back to top]

Number of Patients With Cardiac Arrhythmias

Incidence of new atrial or ventricular arrhythmias from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Metolazone0
Chlorothiazide0
Tolvaptan0

[back to top]

Number of Patients With Escalation of Loop Diuretic Therapy

Provider escalation of loop diuretic dosage at 24 hours for urine output less than 3 L at 24 hours (NCT02606253)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Metolazone4
Chlorothiazide4
Tolvaptan2

[back to top]

Number of Patients With In-hospital Mortality

Incidence of death from study enrollment to hospital discharge, an average of 5 days (NCT02606253)
Timeframe: Enrollment to hospital discharge an average of 5 days

InterventionParticipants (Count of Participants)
Metolazone0
Chlorothiazide0
Tolvaptan0

[back to top]

Number of Patients With New Inotrope Utilization

Incidence of new initiation of dopamine, dobutamine, or milrinone from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Metolazone1
Chlorothiazide0
Tolvaptan2

[back to top]

Number of Patients With Renal Replacement Therapy Utilization

Incidence of Renal replacement therapy utilization (hemodialysis, ultrafiltration) from enrollment to hospital discharge, an average of 5 days (NCT02606253)
Timeframe: enrollment to hospital discharge an average of 5 days

InterventionParticipants (Count of Participants)
Metolazone0
Chlorothiazide0
Tolvaptan0

[back to top]

Number of Patients With Symptomatic Hypotension

SBP < 85 mmHg plus medical intervention for symptomatic hypotension (NCT02606253)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Metolazone2
Chlorothiazide0
Tolvaptan2

[back to top]

Potassium Supplementation

Cumulative dose of potassium supplementation (mEq) administered from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

InterventionmEq (Mean)
Metolazone103
Chlorothiazide63
Tolvaptan58

[back to top]

Weight Change Over 48 Hours

The primary outcome will be 48-hour standing scale weight change (kg) from enrollment among the metolazone, intravenous chlorothiazide, and tolvaptan arms, using metolazone group as the comparator group for all other groups. (NCT02606253)
Timeframe: 48 hours

Interventionkg (Mean)
Metolazone-4.6
Chlorothiazide-5.8
Tolvaptan-4.1

[back to top]

Number of Patients With Hypokalemia

Incidence of hypokalemia (serum potassium less than 3.5mEq/L ) from enrollment to end of study (NCT02606253)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Metolazone3
Chlorothiazide2
Tolvaptan2

[back to top]

Change in eGFR From Baseline to 48 Hours

Change in estimated glomerular filtration rate (ml/min/m2) from baseline to 48 hours (NCT02606253)
Timeframe: 48 hours

Interventionml/min/m2 (Mean)
Metolazone-6
Chlorothiazide-9
Tolvaptan2

[back to top]

Change in Patient Congestion Score

"Participants will score their congestion on a 10cm scale ranging from Best (10cm) to Worst (0cm). Change in score (units in centimeters) from baseline to 48 hours." (NCT02606253)
Timeframe: 48 hours

Interventioncm of dyspena analog scale (Median)
Metolazone4.0
Chlorothiazide3.0
Tolvaptan3.0

[back to top]

Change in Serum Chloride From Baseline

Change in serum chloride (mEq/L) from baseline to 48 hrs (NCT02606253)
Timeframe: 48 hours

InterventionmEq/L (Mean)
Metolazone-7
Chlorothiazide-7
Tolvaptan2

[back to top]

Diuretic Efficiency

Diuretic Efficiency is calculated as 48hr urine output/ 48hr Furosemide equivalents in milligrams (NCT02606253)
Timeframe: 48 hours

InterventionUOP / 40mg IV furosemide (Mean)
Metolazone217
Chlorothiazide294
Tolvaptan326

[back to top]

Mean Change in Glomerular Filtration Rate at Discharge

Mean change in glomerular filtration rate from enrollment to end of study at hospital discharge, an average of 5 days (NCT02606253)
Timeframe: hospital discharge an average of 5 days

Interventionml/min/m2 (Mean)
Metolazone-2
Chlorothiazide-2
Tolvaptan-6

[back to top]

Mean Change in Serum Creatinine

Mean change in serum creatinine (mg/dl) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours

Interventionmg/dl (Mean)
Metolazone0.3
Chlorothiazide0.5
Tolvaptan0.03

[back to top]

All Cause Readmission Within 30 Days

All Cause Readmission Within 30 Days (NCT02620384)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Experimental: Placebo10
Experimental: Metolazone9

[back to top]

Change in Weight First 48 Hours

Change in weight from the date/time of study enrollment (baseline) and 48 hours. (NCT02620384)
Timeframe: 48 hours

Interventionkillograms (Mean)
Experimental: Placebo-3.23227
Experimental: Metolazone-5.93939

[back to top]

Fluid Balance at 48 Hours

Difference in value between input and output in milliliters (ml) at 48 hours. Measurement timing began with administration of first dose of investigational product, ended 48 hours later. Fluid balance = Fluid in minus Fluid out. (NCT02620384)
Timeframe: 48 hours

InterventionMililiters (Mean)
Experimental: Placebo-4260.762
Experimental: Metolazone-6510.091

[back to top]

Heart Failure Readmission Within 30 Days

Heart Failure Readmission Within 30 Days (NCT02620384)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Experimental: Placebo2
Experimental: Metolazone4

[back to top]

Length of Hospital Stay

Length of hospital stay in days (NCT02620384)
Timeframe: Inpatient Hospitalization

Interventiondays (Mean)
Experimental: Placebo5.33
Experimental: Metolazone5.44

[back to top]

Number of Participants With Magnesium Electrolyte Abnormality Requiring Replacement

Number of Participants with severe electrolyte abnormalities requiring aggressive replacement defined as magnesium levels less than 1.5 meq/L during the study. (NCT02620384)
Timeframe: 48 Hours

InterventionParticipants (Count of Participants)
Experimental: Placebo2
Experimental: Metolazone1

[back to top]

Number of Participants With Potassium Electrolyte Abnormality Requiring Replacement

Severe electrolyte abnormalities requiring aggressive replacement defined as potassium levels less than 3.0 meq/L during the study. (NCT02620384)
Timeframe: 48 Hours

InterventionParticipants (Count of Participants)
Experimental: Placebo0
Experimental: Metolazone3

[back to top]

Total Dose Diuretics First 48 Hours

Total dosage loop diuretic in first 48 hours using conversion tool to calculate intravenous Lasix equivalence (NCT02620384)
Timeframe: 48 hours

InterventionMilligrams (Mean)
Experimental: Placebo346.470
Experimental: Metolazone350.160

[back to top]

Total Urinary Output at 48 Hours

Total urinary output in milliliters (ml) at 48 hours. Measurement timing began with administration of first dose of investigational product, ended 48 hours later. (NCT02620384)
Timeframe: 48 hours

InterventionMilliliters (Mean)
Experimental: Placebo6893.777
Experimental: Metolazone9333.288

[back to top]

Degree of Improvement in Dyspnea at 6, 12, 24, 36 and 48 Hours.

Dyspnea assessed at 6, 12, 24, 36 and 48 hours with Modified Borg Scale (1-10). Range is from 1 (very slight) to 10 (maximal) dyspnea. (NCT02620384)
Timeframe: 6, 12, 24, 36 and 48 hours.

,
Interventionscore on a scale (Mean)
Baseline6 hours12 hours24 hours36 hours48 hours
Experimental: Metolazone95.493.982.952.1231.600
Experimental: Placebo96.214.883.772.9242.295

[back to top]

Number of Participants With Inotrope Administration During First 48 Hours

Number of Participants with Inotrope administration during first 48 hours following study enrollment. (NCT02620384)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Experimental: Placebo9
Experimental: Metolazone4

[back to top]

All Cause Mortality at 30 Days

All Cause Mortality at 30 Days (NCT02620384)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Experimental: Placebo1
Experimental: Metolazone4

[back to top]

Change in Total Body Weight

Change in total body weight from baseline value measured prior to metolazone dose to value collected after metolazone dose (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

Interventionkg (Mean)
Metolazone Concurrent Dosing-.6
Metolazone Pre-dosing-8.5

[back to top]

Hypokalemia

Proportion of patients with potassium level less than 4.0 mEq/L measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

InterventionParticipants (Count of Participants)
Metolazone Concurrent Dosing0
Metolazone Pre-dosing1

[back to top]

Hypomagnesemia

Proportion of patients with magnesium level less than 2.0 mg/dL measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

InterventionParticipants (Count of Participants)
Metolazone Concurrent Dosing0
Metolazone Pre-dosing1

[back to top]

Hyponatremia

Proportion of patients with serum sodium level less than 135 mg/dL measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

InterventionParticipants (Count of Participants)
Metolazone Concurrent Dosing0
Metolazone Pre-dosing0

[back to top]

24-Hour Urine Output

Total measured urine output in milliliters produced after metolazone dose is given (NCT03746002)
Timeframe: 24 hours

InterventionmL (Mean)
Metolazone Concurrent Dosing2030
Metolazone Pre-dosing5650

[back to top]

Acute Kidney Injury

Portion of patients with increase in serum creatinine by ≥ 0.3 mg/dL or ≥ 50% from baseline (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

InterventionParticipants (Count of Participants)
Metolazone Concurrent Dosing1
Metolazone Pre-dosing1

[back to top]

Change in Serum Creatinine

Change in serum creatinine from baseline value collected prior to metolazone dose to value collected after metolazone dose (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose

Interventionmg/dL (Mean)
Metolazone Concurrent Dosing0.45
Metolazone Pre-dosing0.38

[back to top]